Atomoxetine Open-Label Trial in ADHD
Atomoxetine (originally named tomoxetine), a new therapy for attention deficit hyperactivity disorder (ADHD) marketed by Eli Lilly, was compared to methylphenidate in a prospective, randomized, open-label study for 10 weeks duration, at the University of Nebraska Medical Center, Massachusetts Genera...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pediatric Neurology Briefs Publishers
2002-07-01
|
| Series: | Pediatric Neurology Briefs |
| Subjects: | |
| Online Access: | https://www.pediatricneurologybriefs.com/articles/1610 |